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ABSTRACT  
Aims: Both hypo- and hyperkalemia can have immediate deleterious physiologic effects; less is 
known about long-term risks. The objective was to determine the risks of all-cause mortality, 
cardiovascular mortality and end-stage renal disease associated with potassium levels across the 
range of kidney function and evaluate for consistency across cohorts in a global consortium. 
Methods & Results: We performed an individual-level data meta-analysis of 27 international 
cohorts (10 general population, 7 high cardiovascular risk, and 10 CKD) in the CKD Prognosis 
Consortium. We used Cox regression followed by random-effects meta-analysis to assess the 
relationship between baseline potassium and adverse outcomes, adjusted for demographic and 
clinical characteristics, overall and across strata of eGFR and albuminuria.  We included 
1,217,986 participants followed for a mean of 6.9 years. Average age was 55±16 years, average 
eGFR was 83±23 ml/min/1.73 m2, and 17% had moderate- to severely-increased albuminuria. 
Mean baseline potassium was 4.2±0.4 mmol/L. The risk of serum potassium of >5.5 mmol/L was 
related to lower eGFR and higher albuminuria. The risk-relationship between potassium levels 
and adverse outcomes was U-shaped with the lowest risk at serum potassium 4-4.5 mmol/L. 
Compared to a reference of 4.2 mmol/L, the adjusted hazard ratio for all-cause mortality was 
1.22 (95% CI: 1.15-1.29) at 5.5 mmol/L and 1.49 (95% CI: 1.26-1.76) at 3.0 mmol/L.  Risks 
were similar by eGFR, albuminuria, renin-angiotensin-aldosterone system inhibitor use, and 
across cohorts.  
Conclusions: Outpatient potassium levels both above and below the normal range are 
consistently associated with adverse outcomes, with similar risk relationships across eGFR and 
albuminuria. 
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INTRODUCTION 
  Abnormal serum potassium levels represent one of the most important electrolyte 
disturbances in clinical practice. Potassium plays a crucial role in normal cell membrane 
electrophysiology, with both hyperkalemia and hypokalemia resulting in electrophysiologic 
perturbations, most importantly in the cardiac system. Abnormalities in myocardial resting 
membrane potential, cardiac depolarization, and myocardial excitability can result in conduction 
system abnormalities, including malignant arrhythmias.1-3 
The kidneys play a central role in potassium homeostasis, with chronic kidney disease 
(CKD) being an especially prominent risk factor for hyperkalemia.4,5 Other risk factors for 
hyperkalemia commonly occur in combination with CKD, including clinical conditions such as 
acute kidney injury, cardiovascular disease (CVD), and diabetes mellitus (DM), and various 
medication classes which affect physiologic processes involved in potassium regulation, such as 
inhibitors of the renin-angiotensin aldosterone system (RAASi).6 There is wide variation in the 
estimates of hyperkalemia incidence and prevalence reported in studies of CKD patients, ranging 
from as low as 7.7% to as high as 73%.7-10 Although patients in the general population are 
reported to have lower risk of hyperkalemia than patients with CKD, with prevalence values 
ranging from 2.6% to 3.5% in Canadian and US studies, many of these studies are limited by 
small sample size or select populations.4,10,11 There are less data on hypokalemia in general. The 
increasing worldwide prevalence of CKD and associated conditions compels a careful 
assessment of the prevalence and long-term risks associated with abnormal potassium levels in 
diverse international populations.12,13  
Hyperkalemia and hypokalemia have been consistently associated with higher short-term 
all-cause mortality in observational studies.8,14-18 Some, but not all, have suggested that risks 
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associated with hyperkalemia are greater in individuals with normal kidney function than in 
those with CKD.10 Notwithstanding the putative role of cardiac arrhythmias in the mortality 
associated with hypo- and hyperkalemia,19 few studies have examined the long-term association 
of abnormal potassium levels with CVD-associated mortality. Furthermore, the effects of 
abnormal serum potassium levels on outcomes in other organ systems, such as the kidneys, 
remain less well studied. In order to better guide clinical practice and future clinical trials, we 
performed a meta-analysis of the prevalence of abnormal potassium levels, risk factors of 
abnormal potassium levels, and long-term associations between potassium levels, all-cause 
mortality, CVD-associated mortality, and end stage renal disease (ESRD) in 27 large and diverse 
international cohorts. For the latter aim, we also evaluated whether risks varied by level of 
kidney function and other clinically relevant characteristics.  
 
METHODS 
Participating cohorts 
The Chronic Kidney Disease Prognosis Consortium (CKD-PC) has been described 
previously; additional information is available in Appendices 1-2.20-24 Briefly, CKD-PC 
incorporates cohorts with at least 1,000 participants (at least 500 participants for those cohorts 
predominantly enrolling persons with CKD [CKD cohorts]), data on serum creatinine and 
albuminuria, and 50 or more events of the outcome of interest (mortality or kidney outcomes). 
The present study included 27 cohorts: 10 general population cohorts, 7 high-risk cohorts in 
terms of cardiovascular risk, and 10 CKD cohorts. Meta-analyses were restricted to participants 
aged ≥18 years old with an available value of potassium at baseline. This study was approved by 
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the institutional review board at the Johns Hopkins Bloomberg School of Public Health 
(Baltimore, Maryland, USA). 
Procedures 
Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI creatinine 
equation.25 In cohorts where the creatinine measurement was not standardized to isotope dilution 
mass spectrometry (IDMS), values were multiplied by 0.95 before eGFR calculation.26 We 
defined diabetes as fasting glucose ≥7.0 mmol/L (126 mg/dL), non-fasting glucose ≥11.1 
mmol/L (200 mg/dL), hemoglobin A1c ≥6.5%, use of glucose lowering drugs, or self-reported 
diabetes. Participants with a history of myocardial infarction, coronary revascularization, heart 
failure, or stroke were considered to have a history of CVD. Measures of albuminuria were the 
urine albumin-to-creatinine ratio (ACR), urine albumin excretion rate, urine protein-to-creatinine 
ratio, or semi-quantitative dipstick protein; urine protein-to-creatinine ratio was converted to 
ACR as previously described.27  
The outcomes of interest were all-cause mortality, CVD-associated mortality and ESRD. 
We defined ESRD as initiation of renal replacement therapy.  
Statistical analysis 
We applied a two-stage meta-analysis, with each study first analyzed individually, and 
followed by a random-effects meta-analysis. The overview of the analysis and analytic notes for 
individual studies are provided in Appendix 2 in the Supplement. We imputed missing values of 
covariates using cohort-specific mean values. Potassium levels, serum creatinine and 
albuminuria, as well as the demographic variables age, gender and race were not imputed. We 
quantified heterogeneity with the I2 statistic and Cochran’s Q test. Since the risk of abnormal 
serum potassium levels and their associated outcomes might vary substantially depending on the 
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type of patient population, analyses were stratified by type of cohort (general population/high 
cardiovascular risk or CKD).  
To assess the cross-sectional associations between kidney function and level of 
potassium, we plotted the distribution of baseline serum potassium levels within categories of 
eGFR using kernel density plots. Next, we modeled the risk of potassium >5.0, >5.5 and <3.5 
mmol/L using logistic regression, adjusting for age, race, sex, systolic blood pressure, 
antihypertensive drugs, total cholesterol, diabetes mellitus, body mass index, smoking, history of 
coronary heart disease or stroke, history of heart failure, eGFR (linear spline with knots at 30 and 
60) and albuminuria (log transformed ACR, or categories of dipstick). For eGFR and ACR, the 
reference point was placed at eGFR 80 ml/min/1.73 m2 and ACR 10 mg/g in the general 
population/high-risk cohorts and eGFR 50 ml/min/1.73 m2 and ACR 50 mg/g in the CKD 
cohorts, with statistical significance at other points determined by the meta-analyzed beta 
coefficient and standard error. We tested whether the relationship between kidney function and 
abnormal potassium levels differed by subgroups of age, race, sex, and diabetes status, by 
including the relevant product term in the regression model, determining statistical significance 
by evaluating the ratio of odds ratios between subgroups at each 1 ml/min/1.73 m2 and 8% 
increment of ACR (pointwise interaction), as done previously.20,28,29 In addition, we assessed the 
relationship between potassium levels >5.5 mmol/L and CKD stages (G1-G5 and A1-A3), with 
the reference placed as G2/A1 in the general population/high risk cohorts and G3b/A2 in CKD 
cohorts. 
To assess the relationship between baseline serum potassium and subsequent adverse 
outcomes, we modeled the adjusted hazard ratios (HRs) of the studied outcomes as a spline 
function of serum potassium concentration, fitting piece-wise linear splines for serum potassium 
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with knots placed at 3.5, 4, 4.5, 5, and 5.5 mmol/L, and adjusting for the same set of covariates. 
Given the importance of kidney function on potassium homeostasis, analyses were performed 
overall and with interaction between potassium and eGFR strata of 60+, 30-59, and <30 
ml/min/1.73 m2, albuminuria levels of <30, 30-299 and ≥300 mg/g, as well as age, race, sex, 
diabetes, status, RAASi use, and diuretic use, determining statistical significance for the 
pointwise interaction at each 0.05 mmol/L of potassium. Analyses were performed using 
Stata/MP 14.2 software for Windows (www.stata.com). We considered P-values <0.05 
statistically significant. 
 
RESULTS 
There were a total of 1,217,986 participants with baseline potassium, eGFR, and 
albuminuria levels across 27 cohorts, followed for an average of 6.9 years (range 2.0 - 19). 
Average (mean ± standard deviation) age was 55±16 years, 40% were female, and 14% were 
black (Table 1).  Average eGFR was 83±23 ml/min/1.73 m2, 17% had moderate to severely-
increased albuminuria, and 46% were on antihypertensive medications. Angiotensin converting 
enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and potassium sparing diuretics 
were used in 31%, 11%, and 3% of individuals at baseline, respectively. Non-steroidal anti-
inflammatory drugs (NSAID) use was reported by 15% (Table S1).  
Prevalence and risk factors of hyperkalemia and hypokalemia 
Overall, average baseline potassium was 4.2±0.4 mmol/L; potassium was higher with 
lower baseline eGFR in both the general population/high cardiovascular risk cohorts (Figure 1) 
and in the CKD cohorts (Figure S1). The prevalence of serum potassium >5.0 mmol/L, serum 
potassium >5.5 mmol/L, serum potassium <4.0 mmol/L, and serum potassium <3.5 mmol/L was 
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3.31% (95% CI: 3.28-3.34%), 0.49% (95% CI: 0.48-0.50%), 23.57% (95% CI: 23.49-23.64%), 
and 1.91% (95% CI: 1.89-1.94%) of individuals in general population/high cardiovascular risk 
cohorts and 17.94% (95% CI: 17.58-18.31%), 4.23% (95% CI: 4.03-4.42%), 12.61% (95% CI: 
12.29-12.93%), and 2.03% (95% CI: 1.90-2.17%) of individuals in CKD cohorts. In the general 
population/high cardiovascular risk cohorts, risk factors for hyperkalemia included male gender, 
non-black race, diabetes mellitus, lower BMI, active smoking, history of coronary heart disease 
or stroke, lower eGFR, higher ACR, use of ACEi, ARB or potassium sparing diuretics, and non-
use of thiazide or loop diuretics (Table S2). The relationship between eGFR and serum 
potassium >5.5 mmol/L was nearly linear; higher ACR was a weaker but independent risk factor 
at levels >37 mg/g (Figure 2A & B). There were no meaningful differences in the relationship 
between eGFR or ACR and potassium levels >5.5 mmol/L among patients with different age 
(<65 years, ≥65 years), gender, race (black, non-black), and presence/absence of diabetes 
mellitus (Figures S2-S5). Relationships between eGFR, ACR, and potassium >5.5 mmol/L were 
also similar in the CKD cohorts (Figure S6), as were the direction of associations with most risk 
factors (Table S3).  Categorical analysis revealed that lower eGFR was associated with higher 
risk of potassium level >5.5 mmol/L independent of ACR levels, whereas the association 
between ACR and hyperkalemia was most apparent at higher levels of eGFR and null at eGFR 
<15 ml/min/1.73m2 (Table S4). Similarly, in CKD cohorts, lower eGFR was a strong risk factor 
for potassium >5.5 mmol/L, whereas higher ACR was weak to null (Table S5). 
Risk factors for hypokalemia in the general population/high cardiovascular risk cohorts 
included younger age, female gender, black race, higher systolic blood pressure, the use of 
thiazide or loop diuretics, lower serum cholesterol, lower BMI, and higher ACR; the use of 
ACEi, ARB, or potassium-sparing diuretics, the presence of diabetes mellitus, and a history of 
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CHD or stroke were protective (Table S2). The association of higher albuminuria level with the 
risk of hypokalemia was weak but nearly linear; the association between eGFR and potassium 
<3.5 mmol/L was fairly flat (Figure 2). Risk factor associations with potassium <3.5 mmol/L 
were generally consistent in direction if weaker in the CKD cohorts, with the exception of the 
use of RAASi medications, which was a stronger protective factor for hypokalemia <3.5 mmol/L 
in the CKD cohorts (Table S3). Neither eGFR nor ACR were significantly associated with 
potassium <3.5 mmol/L in CKD cohorts (Figure S6).  
 
Outcomes associated with serum potassium level 
We observed a total of 151,153 all-cause deaths in 26 cohorts, 9,672 cardiovascular 
deaths in 13 cohorts, and 14,266 ESRD events in 16 cohorts during a mean follow-up period of 
6.9±4.1 years (Table S6). The risk-relationship between potassium and all-cause mortality 
demonstrated lowest risk with serum potassium levels between 4 and 4.5 mmol/L, and higher 
risk outside of the 3.5-5 mmol/L range (Figure 3A). Compared to a reference of 4.2 mmol/L, the 
overall adjusted hazard ratio for all-cause mortality was 1.22 (95% CI: 1.15-1.29) at serum 
potassium 5.5 mmol/L and 1.49 (95% CI: 1.26-1.76) at serum potassium 3.0 mmol/L. These 
associations were qualitatively consistent in the individual cohorts (Figure 4) and there was no 
difference in the risk of all-cause mortality associated with potassium by level of eGFR (Figure 
3B). Risk relationships were similarly U-shaped for cardiovascular mortality and end-stage renal 
disease (Figure 3C & 3D) with qualitative consistency in point estimates (Figures S7 & S8). 
Although confidence intervals were wide, there appeared to be no difference in potassium-
cardiovascular risk relationships by level of GFR (Figure S9A). In contrast, higher levels of 
potassium had a weaker relationship with ESRD in individuals with eGFR <30 ml/min/1.73 m2 
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(Figure S9B). The associations of serum potassium with the studied outcomes were broadly 
similar in individuals of different sex, race, levels of albuminuria, history of diabetes mellitus, 
and ACEi/ARB/potassium-sparing diuretic use; however, the association between lower levels of 
potassium and all-cause mortality appeared slightly weaker in older individuals and those using 
diuretics (Figures S10-S16). Results were also broadly similar in CKD cohorts (Figures S17-
S25).  
 
DISCUSSION 
In this international meta-analysis of 1,215,347 participants in 26 diverse cohorts, we 
describe the prevalence, risk factors and long-term outcomes associated with abnormal 
potassium concentrations. Hyperkalemia and hypokalemia were relatively infrequent in the 
studied populations, especially in participants with normal kidney function. Lower eGFR was a 
strong risk factor for hyperkalemia but not hypokalemia; higher albuminuria was a relatively 
weak risk factor for both. Both hyper- and hypokalemia were associated with significantly higher 
long-term risk of all-cause and CV mortality, and of ESRD. Ideal outcomes were observed with 
serum potassium concentrations of 4-4.5 mmol/L. While abnormal potassium levels were more 
common in individuals with lower estimated GFR and higher albuminuria levels, the relative 
risks associated with hyperkalemia and hypokalemia were similar in patients with various levels 
of kidney function, and in various subgroups divided by age, gender, race, diabetes mellitus or 
treatment with ACEi or ARB. 
Abnormal potassium homeostasis is often mediated by a combination of conditions 
affecting potassium intake, distribution and excretion, including demographic characteristics, 
comorbidities and various medications.6,30 Our results confirm the diversity of the risk factors 
13 
 
determining hyper- and hypokalemia (including comorbidities such as CHF and DM,3 and 
therapeutic interventions like diuretic use and RAAS inhibitors31), and emphasize the central role 
played by the kidneys in potassium homeostasis. Similar to our findings, previous studies have 
found a low prevalence of hyperkalemia in patients with normal kidney function, and markedly 
elevated frequencies in various cohorts with CKD, especially in patients with diabetes mellitus, 
in those with more advanced stages of CKD7,8,10 and in kidney transplant recipients.9 As opposed 
to the widely accepted role of lower eGFR as a risk factor for hyperkalemia, the role of 
albuminuria in engendering this condition has not been previously studied. Our results suggest 
that patients with higher levels of albuminuria had a higher prevalence of both hyperkalemia and 
hypokalemia, although the magnitude of this association was smaller than the relationship 
between eGFR and potassium abnormalities, at least for hyperkalemia. This finding has 
important practical relevance, since patients with higher levels of albuminuria often benefit from 
therapy with RAAS inhibitor medications to slow progression of CKD,32-37 but which also 
increase the risk of hyperkalemia.31,38,39 A secondary analysis of the Reduction of Endpoints in 
NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study showed that 
hyperkalemia after losartan therapy attenuated the renoprotective effect of losartan, suggesting 
that prevention of hyperkalemia might allow for enhanced renoprotection by RAAS inhibitors.40 
Current clinical guidelines recommend concerted efforts to resume RAAS inhibitor therapy in 
patients with CHF, even after episodes of severe hyperkalemia (>6 mEq/l), once the 
hyperkalemia was treated and precautions are taken to monitor serum potassium.31 Recent 
clinical trials suggest that the use of potassium binder medications may allow the use of RAAS 
inhibitors in patients prone to hyperkalemia,41-45 although the long term benefit of such strategies 
on clinical outcomes is yet to be demonstrated.46  
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While the prevalence of serum potassium <3.5 was relatively low, milder forms of 
hypokalemia were very common, especially in general population/high cardiovascular risk 
cohorts. Even mild hypokalemic episodes are clinically relevant in patients at high risk for 
ventricular arrhythmias and sudden cardiac death, such as patients with CHF or DM.3,31,47 
Correction of hypokalemia is relatively easy with dietary or medicinal measures,48 and it is 
recommended as part of strategies to prevent these complications.3  
The U-shaped association of serum potassium levels with clinical outcomes described in 
this study confirm findings from previous studies indicating similar associations with all-cause 
mortality,8,10,14-18 and extends them to an outpatient, large and diverse international population. 
The association between hypo- and hyperkalemia and mortality could be explained by the 
induction of malignant arrhythmias3,19 and their consequences, such as hypotension, myocardial 
ischemia and sudden cardiac death.3,17 In addition, hypokalemia and low dietary potassium 
intake is also associated with hypertension and consequent cardiovascular outcomes such as 
strokes.48 This hypothesis is also supported by the association of hypo- and hyperkalemia with 
cardiovascular mortality in our study. It is perhaps not surprising to see an association of serum 
potassium levels with ESRD, which has been inconsistently detected previously in smaller 
cohort studies.8,40,49,50 Hyperkalaemia that is resistant to treatment is an indication of dialysis 
start and patients who require very high diuretic doses due to volume overload may have lower 
potassium levels and may be started earlier on dialysis. In addition to its link with hypertension, 
hypokalemia is also a risk factor for tubulointerstitial fibrosis and renal cyst formation,51-54 thus 
contributing to the development and progression of CKD. Conversely, hyperkalemia may be a 
surrogate marker of more severe CKD. Further studies are needed to determine if correction of 
hypo- and hyperkalemia could result in improved renal outcomes. 
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Our study is notable for its large size, international representation and diverse patient 
population. Despite its advantages, this study also has limitations. Variation in design across 
cohorts introduces heterogeneity and prevents using time-updated potassium levels, but our 
consistent results across diverse cohorts suggest the robust and empirical long-term association 
of a single measurement, relevant to clinical practice.  Our results were driven largely by 
findings from general population cohorts, with high cardiovascular risk and CKD cohorts 
contributing relatively fewer participants. However, the causes and consequences of abnormal 
serum potassium have been least studied in the general population, hence our emphasis on this 
segment fills an important void. We adjusted for many confounders, but the effect of unmeasured 
confounders (e.g. serum calcium, magnesium and blood pH levels) cannot be ruled out. We 
could not limit the studied medications (e.g. RAAS inhibitors) to new prescriptions, which may 
explain their lack of association with outcomes. 
Conclusions  
The risk factors of abnormal potassium values are diverse, and include low estimated 
GFR, albuminuria, the use of various medications and comorbid conditions such as diabetes 
mellitus. The incorporation of these findings in clinical prediction tools in future studies could 
enhance our ability to risk-stratify patients and to proactively manage hypo- and hyperkalemia. 
Hypo- and hyperkalemia are independently associated with significantly higher all-cause and CV 
mortality, and with higher risk of ESRD, with the best outcomes seen with serum potassium 
levels of 4-4.5 mmol/L. Future research is needed, preferably in the form of a randomized 
controlled clinical trial, to determine if correction of abnormal serum potassium levels can result 
in improvement in mortality and delay onset of dialysis.  
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Figure Titles and Legends: 
 
Figure 1. Distribution of serum potassium concentrations, overall and by baseline estimated 
glomerular filtration rate in general population and high cardiovascular risk cohorts. 
 
Figure 2. Continuous association of estimated GFR (panel A) and albuminuria (Panel B) with 
the risk of serum potassium level >5.5 mmol/L, and of estimated GFR (panel C) and albuminuria 
(Panel D) with the risk of serum potassium level <3.5 mmol/L, in general population and high 
cardiovascular risk cohorts. Black dots indicate statistical significance compared with the 
reference (diamond) estimated GFR of 80 ml/min/1.73m2 (panels A and C) and albuminuria of 
10 mg/g (panels B and D). Adjusted for age, gender, race, systolic blood pressure, 
antihypertensive drugs, total cholesterol, diabetes, body mass index, smoking, history of 
coronary heart disease or stroke, history of heart failure.  
 
Figure 3. Adjusted hazard ratio of all-cause mortality, cardiovascular mortality and end stage 
renal disease associated with serum potassium concentration in general population and high 
cardiovascular risk cohorts. Black dots indicate statistical significance compared with the 
reference (diamond) serum potassium of 4.2 mmol/L. Models adjusted for age, gender, race, 
systolic blood pressure, antihypertensive drugs, total cholesterol, diabetes, body mass index, 
smoking, eGFR, albuminuria, history of coronary heart disease or stroke, history of heart failure. 
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Figure 4. Adjusted relative hazard of all-cause mortality for potassium of 3.0 mmol/L (A) and 
5.5 mmol/L (B), compared to a potassium of 4.2 mmol/L in individual general population/high 
risk cohorts 
